syndromic neurometabolic disease with non-X-linked intellectual disability

ORPHA: 1820733 Treatments Available

Overview

human disease

Available Treatments (3)

DrugFormStatusCountriesLead Time
Vigabatrin
Orphan
Oral tablet 500mg; Oral powder for solution 500mg sachetsFDA Approved, EMA Approved614d
Carnitine
Orphan
Oral tablet 330mg; Oral solution 100mg/mL; IV injection 200mg/mLFDA Approved, EMA Approved97d
Levetiracetam
Oral tablet 250mg, 500mg, 750mg, 1000mg; Oral solution 100mg/mL; IV infusion 500mg/5mLFDA Approved, EMA Approved113d

Classification & Codes

Orphanet Code

ORPHA:182073
syndromic neurometabolic disease with non-X-linked intellectual disability
OrphanetORPHA:182073
Treatments3 drug(s)
Statuspublished
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO
syndromic neurometabolic disease with non-X-linked intellectual disability | OrphanDrug